Beneficios del trasplante fecal en comparación con el uso de Vedolizumab en el tratamiento de enfermedad de Crohn: Revisión sistemática

Abstract

Introduction: Crohn's disease is an inflammatory pathology that is part of inflammatory bowel diseases, and its treatment is challenging due to the goal of achieving complete clinical remission. Objective: To determine the benefits of Fecal Microbiota Transplantation (FMT) compared to vedolizumab therapy in the treatment of Crohn's disease. Methodology: A systematic review was conducted following the 2020 PRISMA statement guidelines, using established eligibility criteria. The risk of bias was assessed using the RoB 2 and JBI tools. Results: Twelve studies (clinical and observational trials) with more than 3,500 patients were included. Vedolizumab showed sustained efficacy and improved validated quality of life, but with frequent adverse events. Fecal microbiota transplantation showed a rapid response, good tolerance, and potential to improve functional symptoms, although with less standardized validation. Discussion: Limitations include methodological heterogeneity, less longitudinal evidence for FMT, and publication bias. However, the results support its complementary or case-specific use